| 0.55 -0.02 (-3.51%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.84 | 1-year : | 1.02 |
| Resists | First : | 0.71 | Second : | 0.87 |
| Pivot price | 0.64  |
|||
| Supports | First : | 0.47 | Second : | 0.39 |
| MAs | MA(5) : | 0.55 |
MA(20) : | 0.68 |
| MA(100) : | 1.31 |
MA(250) : | 3.56 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 23.8 |
D(3) : | 21.5  |
| RSI | RSI(14): 24.4 |
|||
| 52-week | High : | 13.97 | Low : | 0.47 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BJDX ] has closed above bottom band by 18.4%. Bollinger Bands are 55.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 64 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.58 |
| Low: | 0.54 - 0.54 | 0.54 - 0.55 |
| Close: | 0.54 - 0.55 | 0.55 - 0.56 |
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Sat, 02 Mar 2024
BJDX Stock Quote Price and Forecast - CNN
Tue, 02 Jan 2024
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering - GlobeNewswire
Fri, 28 Jul 2023
What's Going On With BlueJay Diagnostics Stock? - Bluejay Diagnostics (NASDAQ:BJDX) - Benzinga
Mon, 24 Jul 2023
Bluejay Diagnostics (NASDAQ: BJDX) to jump 2,000% today - of no great matter - Dhaka Tribune
Mon, 24 Jul 2023
Will Bluejay Diagnostics (NASDAQ:BJDX) Spend Its Cash Wisely? - Yahoo Finance
Thu, 09 Jun 2022
SEAC, BJDX, WEJO, FIVE, AUVI: Trending Stocks Today 9 June - Value the Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 16.9 (%) |
| Held by Institutions | 7.4 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 25 (K) |
| EPS | -9.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.33 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -70.1 % |
| Return on Equity (ttm) | -137.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.07 |
| PEG Ratio | 0 |
| Price to Book value | 0.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|